Trifloxystrobin

1. Distribution of Technical Manufacturing

The manufacturing of technical grade active ingredients is highly concentrated, characterized by “originators holding the core, China dominating capacity with a tech-driven shift, and India accelerating its catch-up.”

• Multinational Originators:
  • Bayer CropScience: As the original developer, Bayer retains significant influence over high-quality technical supply through its European facilities to feed its premium global formulations (e.g., Nativo).
• Key Chinese Suppliers (Tech & Capacity Driven):
  • Currently, Chinese supply is evolving toward an “oligopoly” driven by technology, concentrated in northwestern chemical parks.
  • Technological Breakthrough – CAC Group (Taihe): Leveraging new, patented green synthesis processes for Strobilurin fungicides, CAC Group has significantly reduced the environmental footprint (lower effluent discharge) while improving yield. This provides the most reliable supply guarantee for international buyers seeking long-term stability free from environmental production curbs.
  • Comprehensive Portfolio – Nutrichem (Yingtai): As a top-tier fungicide manufacturer, Nutrichem maintains mature Trifloxystrobin capacity and recently (mid-2026) secured domestic non-exclusive patent licensing for Picoxystrobin. This positions them to offer a complete portfolio of premium fungicide technicals.
  • Strategic Co-Supplier – Hailir Pesticide: Hailir’s absolute core strengths lie in Prothioconazole and Pyraclostrobin. For clients needing both Trifloxystrobin and Prothioconazole for mixtures, Hailir serves as an excellent integrated supply partner.
• India’s Indigenous Rise:
  • Best Crop Science (BCS) became the first indigenous manufacturer of Trifloxystrobin technical in India in 2021. Giants like UPL are also actively pursuing backward integration to reduce reliance on Chinese imports.

1. 原药工厂分布
原药生产高度集中，呈现“原研巨头把控核心、中国主导产能并向技术驱动转型、印度加速追赶”的精确格局。

• 跨国原研巨头： 拜耳 (Bayer CropScience) 作为最初开发者，依然在欧洲（如德国等工厂）和全球供应链中掌握高品质原药的话语权，主要供应其全球高端制剂（如Nativo 拿敌稳）。
• 中国核心供应商 (技术与产能双驱动)： 目前，中国原药供应正向“技术驱动型”与“寡头化”演变，产能集中在西北精细化工园区。
  • 技术突破代表 – 泰禾化工 (CAC Group / 泰诚生物)： 泰禾在甲氧基丙烯酸酯类杀菌剂的合成上布局了重要的新工艺专利。依托先进的绿色合成新工艺，大幅降低了传统路线的环保负担（减少废液排放）并提高了收率。这为海外客户提供了最可靠的长期货源保障。
  • 全品类矩阵代表 – 颖泰生物 (Nutrichem)： 作为国内杀菌剂龙头，颖泰不仅拥有成熟的肟菌酯产能，更在近期（2026年中）拿下了啶氧菌酯的中国境内非独占专利许可，能够为客户提供最全面的高端杀菌剂原药组合。
  • 联合供应商代表 – 海利尔 (Hailir Pesticide)： 海利尔的核心主导原药为丙硫菌唑和吡唑醚菌酯。对于同时需要采购“肟菌酯+丙硫菌唑”进行复配的客户，海利尔是极佳的原药供应链伙伴。
• 印度本土崛起： Best Crop Science (BCS) 于2021年获批，成为印度首家本土制造肟菌酯原药的企业。UPL (安道麦) 等巨头也在积极向原药端延伸，打破对中国原药的完全依赖。

2. Distribution of Formulation Manufacturing

Formulation manufacturing is highly decentralized. Indian formulators are exceptionally active in sourcing technicals, blending, and distributing locally.

• Multinationals: Bayer and Syngenta possess the most mature formulation lines across various regional plants globally.
• Indian Formulation Giants: Companies like Crystal Crop Protection and Coromandel International heavily import technicals to formulate WDGs and SCs. Trifloxystrobin + Tebuconazole is currently the highest-demand formulation in India.
• Chinese Export-Oriented Formulators: Companies like Rainbow Agro and Noposion utilize their global “rapid market access” networks to export finished mixtures directly to LATAM and APAC end-markets.

2. 制剂工厂分布
制剂生产高度分散，贴近终端市场。印度本地制剂厂在消化原药、复配分销方面极其活跃。

• 跨国巨头： 拜耳和先正达拥有全球最成熟的制剂生产线，布局全球区域工厂。
• 印度本土制剂巨头： Crystal Crop Protection、Coromandel International 等公司大量进口中国原药，加工成水分散粒剂 (WDG) 和悬浮剂 (SC)。在印度，肟菌酯+戊唑醇是最火热的配方。
• 中国出口型制剂企业： 润丰股份 (Rainbow Agro) 和 诺普信 (Noposion) 等，依托其全球“快速市场准入”网络，将加工好的复配制剂直接出口至拉美、亚太等终端市场。

3. Distribution of End-Users

The distribution of end-users highly overlaps with global major crop planting areas.

3. 终端使用客户分布
终端分布与全球主要农作物种植区域高度重合。

4. Future Trends: Policy, Market & Product Outlook

• Supply Chain – India’s Backward Integration & Trade Barriers:
  The “Make in India” initiative is heavily subsidizing domestic technical manufacturing. India’s reliance on Chinese technicals will decrease, potentially followed by tariff barriers to protect domestic players.
• Market – Resistance Management Driving the “Mixture Era”:
  Solo Trifloxystrobin is prone to resistance and rarely promoted today. The mainstream future is multi-site mixtures. Beyond classic Trifloxystrobin + Triazoles, the fastest-growing combinations will be Trifloxystrobin + SDHIs (e.g., Fluxapyroxad) to combat severe resistance in LATAM soybean rust.
• Technology – Green Formulations & Biologicals:
  As high-end markets like the EU tighten MRLs, Nano-SC formulations and combinations of “Trifloxystrobin + Biological Fungicides” represent the next blue ocean for premium agricultural markets.

4. 全球未来趋势研判

• 供应链趋势 – 印度的“向后一体化”与贸易壁垒： 印度推行 “Make in India” 强力补贴本土原药制造，未来对中国纯原药的进口依存度将下降，甚至可能筑起关税壁垒保护本土产能。
• 市场趋势 – 抗性管理驱动“绝对复配”时代： 单剂易产生抗性，全球已几乎不再推广。未来绝对主流是多作用机理复配。除了经典的 肟菌酯+三唑类，未来增长最快的是 肟菌酯+SDHI类（如氟唑菌酰胺），用于攻克拉美大豆锈病等严重抗药性。
• 技术趋势 – 绿色剂型与生物融合： 随着欧盟等高端市场收紧MRL（最大残留限量），纳米级悬浮剂 (Nano-SC) 以及“肟菌酯+生物杀菌剂”的混配方案，将成为下一步的行业蓝海。

1. MMTA Manufacturer Audit

English Overview

• Inner Mongolia Factory: Currently in a shutdown state, but holds verified stock. The product quality has been consistently recognized by Indian clients. Strategy: Verify inventory; categorized as “Provisional” (Reliable).
• Liaoning Longtian: A mainstream manufacturer. They produce their own MMTA with a price advantage. However, Indian clients currently have reservations regarding color and yield. Strategy: Requires Pre-shipment Small-scale Testing (PSST); categorized as “Provisional” (Testing phase).
• Jiangxi Oushi: A technical manufacturer. They utilize a verified third-party production system. The quality has been audited and proven consistent. Strategy: Categorized as “Provisional” (Reliable).
• Lanzhou Tuoqiu: Primarily acts as a trader, sourcing MMTA from third-party small plants (e.g., Inner Mongolia). Pricing is higher due to the trading layer. Strategy: Use only for emergency backup.
• Jingzhou Zhongyi: Historically an API manufacturer that traded MMTA. After the failure of their technical R&D transition, they have officially abandoned the MMTA business. Strategy: Removed from vendor list.
• Other Small-scale Plants: Characterized by unstable operations and unreliable quality. Strategy: Do not trust; exclude from sourcing pipeline.

中文审计要点

• 内蒙古工厂：目前处于停车状态，可能有库存。因其质量已获印度客户认可，现阶段暂可作为主要供应源。
• 辽宁龙田：自产肟醚具备明显价格优势，但因印度客户对于其成品药颜色与收率存在疑虑，需通过严格的船前小试验证，现阶段暂可采购。
• 江西欧氏：目前肟醚通过第三方代工生产，代工品质经过验证，现阶段品质稳定，暂可采购。
• 兰州托球：主要作为贸易商，从内蒙古等第三方小厂采购，因贸易加价环节导致价格较高，仅建议作为应急储备。
• 荆州众一：在尝试研发泰禾新技术失败后，已彻底放弃肟醚业务，已从采购清单中剔除。
• 其他小厂：普遍存在开工不稳定、交付延期及质量风险大的问题，均不值得信赖，建议排除。

2. Market Risk & Supply Chain Strategy

In summary, while CAC Group remains a leading API manufacturer, its redesigned API synthesis technology has granted it a significant advantage. To maintain its monopoly, CAC has ceased supplying core intermediates like MMTA to the India market. Furthermore, many small MMTA production plants and contracted organizations in China have ceased operations between 2023 and 2025, as current API prices cannot support MMTA profit margins. Therefore, we firmly believe the current MMTA supply in China is insufficient, and intermediate prices are unlikely to drop significantly in the near term. We strongly recommend that if Indian clients plan to produce Trifloxystrobin technical grade, now is the optimal time to secure MMTA supplies from verified sources to avoid future supply shortages.

总之，尽管泰禾化工 (CAC) 等巨头通过新工艺实现了技术垄断，但由于其策略性停止向印度供应核心中间体，导致市场供给出现缺口。2023至2025年间，大量小规模代工厂因利润无法支撑生产成本而永久关停。TIMGAILE 坚定认为：中国市场的肟醚供应目前处于结构性紧缺，短期内价格难以大幅回落，现在是锁定核心中间体产能的最佳时机。对于计划生产肟菌酯原药的印度客户，我们强烈建议立即通过经我们验证的可靠渠道锁定产能，以规避未来潜在的供应短缺风险。